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Abstract
Background: Monocytes and macrophages are key innate immune effector cells that produce cytokines and chemokines
upon activation. We and others have shown that 17b-estradiol (E2) has a direct role in the modulation of monocyte and
macrophage immune function. However, relatively little is known about the ability of E2 to regulate isoform expression of
estrogen receptors (ERs) in these cells.
Methodology/Principal Findings: In this study, we quantify expression of ERa and ERb in human monocytes and
macrophages. We also show for the first time that the N-terminal truncated ERa variant, ERa46, is expressed in both cell
types. Promoter utilization studies reveal that transcription of ERa in both cell types occurs from upstream promoters E and
F. Treatment with E2 induces ERa expression in macrophages but has no effect on ERb levels in either cell type. During
monocyte-to-macrophage differentiation, ERa is upregulated in a time-dependent manner. Previous studies by our group
demonstrated that E2 treatment attenuates production of the chemokine CXCL8 in an ER-dependent manner. We now
show that ERa expression levels parallel the ability of E2 to suppress CXCL8 production.
Conclusions/Significance: This work demonstrates for the first time that human macrophages predominantly express the
truncated ER variant ERap46, which is estradiol-inducible. This is mediated through usage of the ERa F promoter. Alternative
promoter usage may account for tissue and cell type-specific differences in estradiol-induced effects on gene expression.
These studies signify the importance of ERa expression and regulation in the ability of E2 to modulate innate immune
responses.
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Introduction
Monocytes are released from the bone marrow into circulation
and extravasate into peripheral tissues, where they differentiate
into macrophages [1]. As key phagocytes, monocytes and
macrophages provide both early recognition of pathogens and a
crucial bridge between innate and adaptive immunity. The innate
immune system deploys rapid antimicrobial responses to patho-
genic challenge and simultaneously instructs the adaptive immune
system regarding the nature and context of the infectious threat.
Activation of innate immunity is mediated through recognition of
distinct molecules that are present on a broad diversity of
microorganisms. These pathogen-associated molecule patterns
(PAMPs) are recognized by Toll-like receptors (TLRs) that are
expressed by monocytes and macrophages. Lipopolysaccharide
(LPS), a component of Gram-negative bacterial cell walls, binds to
its receptor TLR-4 and activates signaling cascades that result in
the elaboration of cytokines and chemokines [2]. Production of
these factors is important for the recruitment of other inflamma-
tory effector cells and the activation of adaptive immunity.
Macrophages activate adaptive immune responses by phagocy-
tosing foreign molecules and displaying antigens on their surface
for recognition by T lymphocytes. The phenotype and function of
tissue macrophages are affected by and uniquely dependent on the
cellular milieux to which they are exposed, which include
cytokines, chemokines and other biological effector molecules
such as steroid hormones. In this regard, recent studies have
shown that 17b-estradiol (E2) mediates profound effects on
monocyte and macrophage immune function [3].
E2 is the major circulating estrogen in pre-menopausal females
and has a direct role in the modulation of innate immune function.
Previous studies have shown that E2 attenuates production of pro-
inflammatory cytokines including IL-6, TNFa and macrophage
inhibitory factor [4,5,6]. Moreover, we have shown that expression
of the proinflammatory chemokine CXC-motif ligand8 (CXCL8)
is also decreased by E2 in monocytes that have been challenged
with LPS [7]. CXCL8 is central to the recruitment of neutrophils
to sites of inflammation, where they aid in mediating pathogen
clearance [8]. As a consequence of their role in microbial
destruction, neutrophils also damage tissue at infected sites,
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immune defense [9].
E2 signals are transduced through estrogen receptors, ERa and
ERb. ERs are ligand-inducible transcription factors and are
members of the nuclear hormone receptor family. The ability of
ERs to modulate transcription requires the recruitment of co-
regulatory proteins to the promoters of estrogen-regulated genes
through both direct and indirect interactions. In the classical
model of E2 action, binding of E2 to intracellular ERs induces
retention of the activated steroid-receptor complex in the nucleus.
This complex then augments or represses estradiol-specific gene
expression by binding with high affinity to sequence-specific cis
regulatory motifs contained within the promoters of target genes
(reviewed in [10]). These sequences contain a 13 bp palindromic
motif (GGTCAnnnTGACC) referred to as the estrogen responsive
element (ERE) [11]. Notably, the ERa promoter contains a half
ERE consensus binding site [12]. ERE half sites have been shown
to mediate transcriptional regulation of many estrogen-responsive
genes, including breast cancer 1 associated ring domain 1
(BARD1) and bone morphogenetic protein-6 (BMP-6) [13,14].
Although ERa and ERb arise from separate genes on different
chromosomes, they share a high degree of overall homology,
particularly in the DNA binding domain [15]. The general
structure of the ER consists of an N-terminal activator function-1
domain (AF-1), which is followed by the DNA binding domain, a
dimerization domain and the ligand binding / AF-2 domain. The
AF domains function as co-regulator binding sites. AF-1 cofactor
recruitment is independent of ligand binding and AF-2 cofactor
recruitment is dependent on ligand binding [16]. The ERa gene is
transcribed from at least six up-stream promoters, which results in
mRNA products that differ in their 59 untranslated regions
(59UTRs) and produce the full-length 66 kDa ERa (ERa66) [17].
Alternative splicing of upstream exons directly into exon 2 results
in the AF-1 domain-truncated 46 kDa variant of ERa (ERa46)
[18,19]. A 36 kDa ERa variant (ERa36) lacking both AF-1 and
AF-2 domains has also been recently described [20]. Similarly,
ERb is transcribed from at least two additional upstream
promoters and alternative splicing leads to at least five protein
isoforms (ERb1-5) [15].
Recent work has begun to characterize expression of ERa and
ERb isoforms in cells and tissues, and these results suggest that
differences in the expression of ER isoforms influence gene
regulation. For example, the 46 kDa ERa isoform, which has been
identified in human endothelial cells [21], osteoblasts [19] and the
breast carcinoma cell line MCF-7 [18], has been shown to repress
the AF-1 activity of full-length ERa 66 [18]. Furthermore, studies
conducted by Metivier et al suggest that ERa46 selectively
represses transcription of the E2-responsive pS2 gene through the
recruitment of corepressors [22,23]. This is in marked contrast to
full length ERa66, which mediates transcriptional activation of the
pS2 gene [23]. Therefore, altered expression of ERa46 vs. ERa66
may account for differential effects of estradiol on gene expression.
Although estradiol has been shown to directly affect monocyte
and macrophage immune function, relatively little is known about
ERa isoform expression and the ability of estradiol to modulate
expression of ER isoforms in these cells. In this study, we
demonstrate for the first time that full length ERa66 and the
ERa46 splice variant are expressed in primary human monocytes
and macrophages. Since previous studies suggest that E2
modulates ER expression in other cell types [24,25,26,27], we
asked whether E2 regulates ER expression in monocytes and
macrophages. We now show that E2 induces ERa46 in
macrophages, but has no effect on ERa expression in monocytes.
In contrast, E2 does not regulate ERb expression in either cell
type. Finally, we provide evidence of a direct correlation between
ERa expression levels and suppression of LPS-induced CXCL8
secretion. This may be significant for the reduction of tissue
damage induced by excessive recruitment of leukocytes, particu-
larly neutrophils, during an immune response. Collectively, these
findings indicate the importance of alternative ERa isoform
expression and implicate a role for estradiol in the regulation of
monocyte and macrophage activation.
Results
Expression of ERa and ERb quantitatively differs in
primary human monocytes and monocyte-derived
macrophages
We and others have reported expression of ERs in human
monocytes [7,28,29] and macrophages [30,31,32]. However,
expression of ERa and ERb had not been quantified in these
cell types. Using quantitative Taqman PCR, we demonstrated that
ERa mRNA was expressed at higher levels than ERb in both
freshly isolated monocytes (M0) and macrophages that had been
differentiated with GM-CSF for 7 days. Although macrophages
expressed higher levels of ERa message relative to monocytes,
ERb message levels were lower in macrophages when compared
with monocytes (Figure 1A). Consistent with these findings, total
ERa protein levels were significantly higher in macrophages, while
ERb protein expression was greater in monocytes (Figure 1B–D).
Three ERa isoforms have been reported: full length ERa
(ERa66) and the splice variants ERa46 and ERa36. Consistent
with previous reports [20,33], we were able to detect all three
isoforms of ERa in MCF-7 breast cancer cells (Figure 1B). In
addition to expression of ERa66, we also detected expression of
ERa46 in both human primary monocytes and monocyte-derived
macrophages (Figure 1B). Intriguingly, monocytes expressed
equivalent levels of both isoforms, whereas macrophages expressed
more ERa46 relative to ERa66 (Figure 1E). These data are
particularly significant because ERa46 has been shown to function
as a repressor of ERa66 transcription [18,19,34].
Estradiol increases ERa expression in macrophages, but
not monocytes
Previous work has demonstrated that E2 modulates ER
expression in endometrial carcinoma cells [24]. To determine
whether E2 regulates ER expression in monocytes and macro-
phages, cells were treated with 10
27 M E2 for 72 hrs. In this study,
freshly isolated monocytes were cultured with estradiol for 72
hours. To distinguish these cells from the freshly isolated
monocytes in Figure 1, we refer to these cells as M72. M72
monocytes have been cultured for a full 72 hours longer than the
M0 monocytes in Figure 1. Fully differentiated GM-CSF-matured
macrophages were also treated with estradiol for 72 hours.
Following treatment, M72 monocytes and macrophages were
lysed and ER mRNA and protein expression levels were assayed.
As demonstrated in Figure 2 (A and C), E2 treatment induced
ERa mRNA and protein expression in macrophages, but had no
effect on M72 monocyte ERa levels. In contrast, E2 had no effect
on ERb expression in either cell type (Figure 2B and C). The E2-
induced increase in total macrophage ERa protein levels can be
attributed predominantly to up-regulation of ERa46 (Figure 2C
and D). To determine whether E2 influenced ERa mRNA
expression at earlier time points, GM-CSF-matured macrophages
were treated with E2 or vehicle control, and ERa message was
measured over the course of 72 hours (Figure 2E). We observed a
small and transient increase at 6 hrs that returned to base line by 8
hrs, followed by a large increase in ERa message at 72 hrs. E2
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macrophages as measured by CellTiter-Blue viability assay at any
of the time points analyzed (Figure S1).
ERa increases during monocyte-to-macrophage
differentiation
The observation that macrophages express higher levels of ERa
mRNA and protein than monocytes (Figure 1) led us examine
whether ERa is up-regulated during the differentiation of
monocytes to macrophages. To address this question, monocyte
ERa mRNA levels were measured during the first three days of
cell culture in the absence of added cytokine. We also examined
whether E2 treatment during differentiation influenced ERa
expression. Monocytes were cultured for 0, 24, 48, or 72 hrs in the
presence and absence of E2. As shown in Figure 3A, ERa mRNA
expression increased in a time-dependent manner, and this
occurred irrespective of E2 treatment. Consistent with this finding,
ERa46 protein expression was significantly higher after 72 hrs
compared to time 0 (Figure 3B). Moreover, by day 3 of culture, the
expression profiles of ERa66 and ERa46 in M72 monocytes
reflected those of fully differentiated macrophages (Figure 3C).
These data are consistent with our finding that monocytes begin to
assume macrophage-like characteristics with increased duration of
cell culture (Figures 3D and 3E). To determine the differentiation
status of these cells, flow cytometric analysis of key cell-surface
markers was performed. Consistent with the findings of Martinez
et al. and Lehtonen et al. [35,36], we observed that expression of
CD14, MHC II and CD16 increases as monocytes begin to
differentiate into macrophages (compare M0 with M72 mono-
cytes) and that fully differentiated macrophages exhibit higher
levels of cell surface CD14, MHC II and CD16 (Figure 3E). These
observations illustrate that during monocyte-to-macrophage
differentiation, ERa is up-regulated in a time-dependent manner.
Furthermore, these studies show that estradiol induces ERa
expression only in completely differentiated macrophages, since
estradiol treatment failed in increase ERa levels in M72
monocytes (Figure 3A) but did enhance ERa expression in GM-
CSF-matured macrophages (Figure 2C).
ERa is transcribed from upstream promoters E and F in
monocytes and macrophages
Transcription of ERa occurs from at least seven different
promoters, resulting in mRNAs that differ in their 59 UTRs [17]
(Figure 4A). Translation of messages produced from all promoters
Figure 1. Estrogen receptors are differentially expressed in monocytes and macrophages. A, total ERa and ERb mRNA from M0
monocytes and macrophages from 3–4 individual donors were measured using TaqMan real-time PCR and values were normalized to b-actin. B and
C, expression of ERa and ERb protein was assessed by western blot analysis. Blots for GAPDH serve as a loading control. D, densitometry of total ERa
protein expression normalized to GAPDH for three individual donors. E, the relative expression of ERa66 and ERa46 expressed as percent total ERa. *,
p,0.05 vs ERb. #,p ,0.05 vs monocytes.
doi:10.1371/journal.pone.0005539.g001
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messages transcribed from the distal promoters E and F can also
result in production of the ERa46 isoform [12]. Since promoter
usage varies among tissues and cell types [16], we investigated
which promoters were utilized by monocytes and macrophages
and whether they were regulated by E2. To address these
questions, primers were designed such that the forward primers
were specific for the 59 UTR of the ERa mRNA produced by
transcription from each promoter and the reverse primer was
directed towards exon 2 of the coding sequence (Table 1). Each
reaction amplified only messages produced from the given
promoter analyzed. Using MCF-7 cells as a positive control,
RT-PCR analysis confirmed utilization of promoters A–F [16].
Interestingly, both monocytes and macrophages utilize only
promoters E and F for the transcription of ERa (Figure 4B). To
determine whether E2 influences promoter usage, monocytes and
macrophages were treated with E2 for 72 hrs and promoter usage
was analyzed. As demonstrated in Figure 4B, treatment of
monocytes with E2 resulted in preferential utilization of promoter
E vs. promoter F. However, macrophages continued usage of both
promoters and appeared to increase transcription from promoter
F (Figure 4B). Therefore, the disparity in E2 regulation of ERa
expression in monocytes and macrophages may be attributable to
differential promoter utilization.
Figure 2. Estradiol induces ERa expression in macrophages and not monocytes. Monocytes (M72) and macrophages were treated with
10
27 M E2 or ethanol control for 72 hrs and A,E R a and B,E R b mRNA levels were measured. C,E R a and ERb protein were also analyzed. D,
quantification of macrophage ERa46 expression with and without E2 treatment from three different donors normalized to GAPDH expression. E, time
course of ERa mRNA expression in macrophages treated with or without E2 normalized to b-actin and expressed as percent control. *, p,0.05 vs.
control.
doi:10.1371/journal.pone.0005539.g002
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by a half ERE site
E2 modulates transcriptional regulation of gene expression
through selective binding to EREs, and the ERa F promoter
contains a half ERE consensus binding site [11,12]. To elucidate
the role of this half ERE in the E2-mediated induction of ERa46
expression in macrophages, an ERa F promoter luciferase
expression vector was constructed that contains a mutation in
the half ERE site (2117181 to 2117177). RAW264.7 macro-
phages that endogenously express ERa were transfected with this
construct, treated with estradiol and analyzed for ERa promoter
activation. As demonstrated in Figure 5, mutating the ERE
completely abrogated the ability of E2 to induce ERa F promoter-
driven luciferase expression. Intriguingly, mutations in the ERE
also inhibited basal ERa transcription (Figure 5). These studies
implicate a role for the ERE in mediating estradiol induction of
ERa46 expression in macrophages.
ERa levels mirror attenuation of LPS-induced CXCL8
production
Recognition of PAMPs by TLRs activates monocytes and
macrophages to produce cytokines and chemokines. LPS binding
to TLR4 induces production of CXCL8, which attracts neutro-
phils to sites of inflammation. Neutrophils aid in pathogen
clearance via phagocytosis and the release of proteolytic enzymes.
In this regard, neutrophils are beneficial in resolving the infection.
However, excessive neutrophil infiltration can cause significant
tissue damage [8].
Previously, we have demonstrated that E2 attenuates LPS-
induced CXCL8 production and subsequently reduces neutrophil
chemotaxis [7]. To test the hypothesis that ERa expression
levels directly contribute to the ability of E2 to suppress CXCL8,
monocytes were cultured for 24, 48 or 72 hrs to allow for
time-dependent increases in ERa expression. During the final
24 hrs of culture, E2 or vehicle control was added to the
Figure 3. ERa expression increases during monocyte-to-macrophage differentiation. A, monocytes were cultured for 0, 24, 48 or 72 hrs
with 10
27 M E2 or ethanol control and ERa mRNA expression was measured and normalized to b-actin expression. B,E R a protein expression of
monocytes (M72) cultured for 0 hrs and 72 hrs. C, comparison of ERa66 and ERa46 expression at 0 and 72 hrs expressed as percent total ERa.* ,
p,0.05 compared to monocytes. D, flow cytometric analysis of freshly isolated monocytes (M0), monocytes cultured for 72 hours (M72), and
monocytes differentiated with GM-CSF for 7 days (macs). Cells were stained for surface expression of CD14, MHC II and CD16. E, change in mean
fluorescence intensity in monocyte expression of CD14, MHC II and CD16 following 0, 24 hrs, 48 hrs and 72 hrs of culture.
doi:10.1371/journal.pone.0005539.g003
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10 ng/ml LPS for 12 hrs. Culture supernatants were analyzed
for CXCL8 production by ELISA and as expected, at all
three time points LPS induced robust production of CXCL8
compared with unstimulated cells (Figure 6). There were no
significant differences in CXCL8 production in 24 or 48 hr
cultures whether they were treated with E2 or not. Importantly,
monocytes cultured for 72 hrs and treated with E2 produced
significantly lower levels of CXCL8 compared with vehicle control
(Figure 6). As we have demonstrated previously, attenuated
CXCL8 production is not attributable to impaired cell viability,
as estradiol treatment does not induce apoptosis in M72
monocytes [7]. These findings suggest that expression of the
ERa46 isoform is coincident with attenuation of LPS-induced
CXCL8 production.
Discussion
Many studies have reported direct modulation of innate
immune function by E2; however, the isoform expression profile
Figure 4. ERa promoter utilization in monocytes and macrophages. A, schematic representation of the ERa promoter. Boxes A–F represent
up-stream exons and forward arrows denote transcription start sites. The inverted open triangle indicates the primary splice acceptor site and the
inverted closed triangle represents the alternative splice acceptor site responsible for ERa46 message. Exons E and F splice into exon E1 before
splicing to the ERa coding sequence. B, cells were treated as in Figure 2 and RT-PCR analysis was performed using forward primers specific for each
upstream exon and a reverse primer specific for exon 2 (see Table 1) to determine ERa promoter usage. Reactions for b-actin were used as a control
for cDNA integrity.
doi:10.1371/journal.pone.0005539.g004
Table 1. Primer sequences for promoter utilization studies.
Primer Name Sequence
Promoter A forward 59-CATGCGCTGCGTCGCCTCTAA-39
Promoter B forward 59-GCCCAGTCTTCCCTGGGC-39
Promoter C forward 59-CCACTCGCACATGCGAGCAC-39
Promoter D forward 59-GTGGGGCTGGAGACACATTCAACG-39
Promoter E forward 59-GCAGTCAGAGAAATAATCGCAGAGCCTCAAATA-39
Promoter F forward 59-CATGGTCATAACAGCCTCCTGTCTACCG-39
ERa exon 2 reverse 59-GCTCAGCATCCAACAAGGCACTGA-39
b-actin forward 59-TCTCTTGCTCTGGGCCTCGTC-39
b-actin reverse 59-TCGCCGCGGTCGTCGTC-39
doi:10.1371/journal.pone.0005539.t001
Figure 5. Estradiol induction of ERa promoter activity is
mediated by a half ERE site. RAW 264.7 cells were transiently
transfected with the pGL4 luciferase expression vector containing either
the wild-type ERa promoter F (pGL4-PF) or the half ERE mutated
promoter F (pGL4-PF-mut ERE). Cells were treated with 10
27 M E2 for 48
hrs and then analyzed for luciferase activity. Results are expressed in
relative light units normalized to vehicle-treated empty vector and are
representative of at least three independent transfections. *p,0.05 vs.
vehicle control.
doi:10.1371/journal.pone.0005539.g005
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unknown. Here we report differential ERa isoform expression in
primary human monocytes and monocyte-derived macrophages.
In addition to the full-length ERa66, we demonstrate for the first
time that the ERa46 variant is expressed in both cell types.
Promoter usage studies revealed that transcription of ERa occurs
from the upstream promoters E and F in monocytes and
macrophages. In addition, E2 treatment induced ERa expression
in macrophages, but had no effect on monocyte ERa levels. E2
had no effect on ERb expression in either cell type. During
monocyte-to-macrophage differentiation, ERa levels increased in
a time-dependent manner. Functional studies provide a direct
relationship between ERa expression level and E2 suppression of
LPS-induced CXCL8 production. Taken together, these data
highlight the role of ERa expression and regulation in E2
modulation of the innate immune response to endotoxin
challenge.
Our current findings show that expression of ERa is greater
than ERb in both monocytes and macrophages. Macrophages
express higher levels of ERa and lower levels of ERb than
monocytes. Although ERa and ERb share a high degree of
homology and ligand specificity, their gene targets differ
substantially [35]. In fact, many immune effects attributed to E2
in monocytes and macrophages are thought to be mediated
through ERa and not ERb [36,37,38,39].
The ERa variant, ERa46, was identified in both cell types along
with the full-length ERa66. Intriguingly, monocytes and macro-
phages also differ in the pattern of ERa66 and ERa46 expression.
Monocytes express equivalent levels of the two proteins, while in
macrophages ERa46 is more highly expressed than ERa66.
Osteoblasts are another cell type that, like the monocyte lineage,
also arise from CD34
+ hematopoietic progenitor cells [40].
Interestingly, osteoblasts also express both ERa66 and ERa46
[19]. Another innate immune cell type, the dendritic cell,
differentiates from monocytes and shares some overlapping
immunological function with macrophages. In a recent publica-
tion, Nalbandian et al. demonstrate that blocking ERs impairs
proper dendritic cell differentiation [41]. These findings, in
conjunction with our observation that ERa is up-regulated during
macrophage differentiation, suggest an important role for ER
signaling during the differentiation of innate immune cells.
The organization of the ERa gene is complex, with at least six
distal promoters described to date [17]. Splicing of upstream exons
prior to the first coding exon results in messages that differ in their
59 UTRs, and translation of these messages produces full length
ERa66. Alternative splicing of upstream exons E and F directly
into exon 2 of the ERa gene is responsible for production of the
ERa46 isoform. Using RT-PCR, we demonstrated usage of both
promoters E and F in monocytes and macrophages, consistent
with expression of ERa66 and ERa46. Although little is known
about auto-regulation of ERa, two promoters have been
previously identified as E2-inducible: promoters C [27] and F
[42]. We demonstrated that macrophages preferentially use
promoter F and that E2 treatment augments total ERa mRNA
and ERa46 protein expression. However, in monocytes E2 had no
effect on promoter E usage, but abrogated the usage of promoter
F. These findings allow us to conclude that through distinctive
changes in promoter usage with E2 treatment, macrophages are
able to up-regulate ERa expression with E2 treatment, whereas
monocytes do not.
One possible explanation for this observation could be that
since macrophages express higher levels of ERa, E2 signaling may
be enhanced in these cells, thereby allowing for ERa auto-
regulation. In this study, we have shown that estradiol enhances
ERa F promoter activity and have identified a half ERE site as the
key mediator of this induction. This is in accordance with the
findings of Lambertini et al, who demonstrated a key role for the F
promoter half ERE site in estradiol-mediated induction of ERa in
human osteoblasts [43]. Intriguingly, mutation of the F promoter
ERE also inhibited basal transcription in the absence of hormone
treatment (Figure 4). In this regard, recent work has shown that
unliganded ER acts as a transcriptional co-activator through
association with the transcription factors c-jun and NFkB [44].
Therefore, it is possible that ERa activates transcription through
association with co-activators while it is bound to the ERE and can
no longer associate with these proteins when the ERE is mutated,
resulting in transcriptional repression. Alternatively, unliganded
ERa may complex with other proteins, bind different transcrip-
tional regulatory sites and inhibit basal transcription. Notably, ERs
have been shown to modulate gene expression in the absence of
ERE binding through association with transcription factor binding
elements such as CRE-D1 [45].
Time course studies in macrophages over a period of 72 hrs
showed a small and transient increase in ERa at 6 hrs E2
treatment; however, the major induction of ERa mRNA occurred
at 72 hrs. The time frame in which we observed induction of ERa
suggests an intermediate factor regulated by E2 activates ERa
expression. One potential intermediate is the homeodomain
transcription factor BARX2. Over-expression of BARX2 resulted
in a 2-fold increase in ERa66 and a 5-fold increase in ERa46 in
MCF-7 cells [46]. Moreover, there is a homeobox binding site
directly upstream of the half ERE in the ERa F promoter (our
unpublished observation). Although it is unknown whether E2
modulates BARX2 expression, there are multiple elements within
the BARX2 promoter that suggest potential regulation by E2.
Notably, there are several EREs within 1 kb upstream of the
BARX2 gene, in addition to binding sites for AP-1 and SP-1
transcription factors (our unpublished observations). It is possible
that E2 up-regulates BARX2, which in turn induces ERa
transcription. This could occur with BARX2 acting alone or in
concert with ERa binding to the half ERE site in the F promoter
[46].
Figure 6. ERa expression mirrors E2 modulation of LPS-
induced CXCL8 production. Monocytes were cultured for 24, 48
or 72 hrs. 10
27 M E2 or ethanol control was added during the final 24
hrs of culture. Subsequently, cells were stimulated in the presence or
absence of LPS (10 ng/ml), for an additional 12 hrs. Culture
supernatants were analyzed for CXCL8 by ELISA and reported as pg/
ml. *, p,0.05 vs. control + LPS.
doi:10.1371/journal.pone.0005539.g006
Estradiol Regulates ER Levels
PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5539In this regard, our findings demonstrating the importance of
timing of E2 treatment are consistent with recent studies
conducted by Calippe et al., who have shown in murine
macrophages that short vs. long-term exposure to estradiol
mediates differential effects on cytokine production [47]. Our
current work demonstrates that treatment with E2 for 6 hours
induced a transient elevation in ER expression in human
macrophages, but it was only after a 72 hour incubation with
E2 that ER expression levels were markedly elevated. These results
suggest that induction of ER expression was not observed in
monocytes but was seen in macrophages because of the timing
required for this E2-mediated event.
Exposure to E2 can alter the innate immune response to
infection. Recent work has shown that E2 decreases production of
multiple cytokines and chemokines in response to inflammatory
signals [4,5,6,7] and gender-based studies in humans have
established sexual dimorphisms in immune responses. For
example, pre-menopausal females have a lower incidence of
trauma related sepsis in comparison to males [39]. Moreover,
post-menopausal women have an increased sepsis mortality rate
compared to pre-menopausal women [3,39]. These findings imply
that hormonal modulation of innate immune function may play a
role in mediating these effects. We now show that after 72 hrs of
culture, the ERa expression profile of monocytes changes to that
of fully differentiated macrophages, in which ERa46 is the
predominant receptor isoform. Significantly, E2 pretreatment of
these cells attenuated LPS-induced CXCL8 production. Together,
these observations designate a role for sex hormones in modulating
immune responses.
In initial studies, we demonstrated that estradiol modulates ERa
expression in a dose-dependent manner. We chose to perform the
remainder of our work with 10
27M estradiol because it
demonstrated the maximal effect on ERa46 induction in
macrophages. This concentration is physiologically relevant
because it is consistent with levels present in the human female
reproductive tract during ovulation. Estradiol levels in the ovarian
vein, which drains directly into the human female reproductive
tract, are 14–80 fold higher during ovulation than levels measured
in peripheral blood, and more than 100-fold higher than during
the early proliferative phase of the menstrual cycle [48]. Estrogen
has been shown to accumulate in the cycling human uterine
endometrium and vagina to at least 37 and 11 times that seen in
plasma, respectively [49]. Therefore, macrophages at these sites
are routinely exposed to this concentration of estradiol. Intrigu-
ingly, 10
27M estradiol also has physiologic relevance during
pregnancy [50,51], and thus our studies may have significant
immunologic relevance at this time.
ERa46 is a functional E2 receptor that can form homodimers as
well heterodimers with ERa66 and ERb. Intriguingly, ERa46
homodimers have a higher affinity for the ERE than ERa66
homodimers. Transcriptional activation of genes that are induced
by E2 and dependent on AF-1 domain cofactor binding are
repressed in systems where ERa46 is over-expressed, indicating
that ERa46 can block ERa66-mediated transcription [18,34].
Previously, we have shown that E2 modulation of CXCL8
production occurs via transcriptional inhibition [7]. Given these
data, it is possible that ERa46 mediates suppression of CXCL8
transcription via suppression of ERa66. Although the role of
ERa46 in regulating immune function has yet to be defined, these
studies suggest the importance of alternative ERa isoforms in
regulating monocyte and macrophage responses to endotoxin
challenge.
Furthermore, differential expression of ERs in monocytes and
macrophages may account for the well-documented variations in
the effects of estradiol in these and other cell types. The ability of
estrogen to transduce signals may be dependent on the ratio of
cellular ER isoform expression. In this model, estradiol selectively
enhances or represses gene expression based on the dominant ER
isoform expression and profile of cofactors present in the cell.
Thus, estradiol will have different effects on cell types in which full-
length ERa predominates vs. the ERa46 splice variant. The
influence of these isoforms on cytokine gene expression in
monocytes and macrophages is under current investigation in
our laboratory.
Here we report, for the first time, the expression of the ERa46
splice variant in human monocytes and macrophages. Further-
more, we demonstrate that estradiol regulates ERa expression in
macrophages and show that increased expression of ERa46 is
concomitant with the ability of estradiol to attenuate CXCL8
expression in response to endotoxin. As CXCL8 is a potent
chemo-attractant for neutrophils, suppression of this chemokine by
E2 may be important in reducing excess neutrophil infiltration
during an immune response and thereby reducing tissue damage.
This may be of particular importance in tissues subject to
physiologically high levels of E2, such as the female reproductive
tract. In fact, CXCL8 expression in these tissues is repressed when
E2 levels are elevated [52] and excessively high levels of CXCL8
correlate with infertility [53,54]. The studies presented here
therefore have broad clinical implications and suggest a role for E2
in the modulation of immune responses during an endotoxin
challenge.
Materials and Methods
Isolation and culture of human peripheral blood
monocytes and macrophages
Peripheral blood mononuclear cells were obtained by leuka-
pheresis of normal, healthy pre-menopausal female donors
following informed consent. Written consent was obtained
from all subjects in accordance with the human experimentation
guidelines established by Dartmouth College’s Committee for
the Protection of Human Subjects (CPHS), protocol #17011.
To preclude confounding results associated with exogenous
hormone use, individuals using hormonal contraceptives were
excluded from these studies. Mononuclear cells were separated on
Ficoll-Hypaque and enriched for monocytes using cold aggrega-
tion [55]. This methodology is based upon the ability of
mononuclear cells to spontaneously form large cellular aggregates
at 4uC and has been used extensively to purify human monocytes
[7,56,57]. Monocyte purity was .98% as determined by CD14
expression using flow cytometry (data not shown). Freshly isolated
monocytes are designated as M0 in the text. In some experiments,
monocytes were cultured in the absence of cytokine for 72 hours
and treated or not with hormone. These cells are indicated in the
text as M72 monocytes. To generate macrophages, monocytes
were cultured in the presence of 10 mg/ml GM-CSF (Peprotech)
for 7 days. Both human monocytes and macrophages were
cultured in complete HEPES-buffered RPMI 1640 (Cellgro)
supplemented with 10% FBS (Hyclone) and 50 mg/ml gentamicin
sulfate (Sigma-Aldrich).
Cell lines and cell culture
The MCF-7 and T47D breast cancer cell lines (ATCC) and
RAW264.7 cells were cultured in HEPES-buffered RPMI 1640
(Cellgro) supplemented with 10% FBS (Hyclone) and 50 mg/ml
gentamicin sulfate (Sigma-Aldrich).
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Prior to hormone treatment, culture media was switched to
HEPES-buffered phenol red-free RPMI 1640 (Cellgro) supple-
mented with 10% charcoal dextran-stripped FBS (Hyclone) and
50 mg/ml gentamicin sulfate. Phenol red-free media were used to
exclude estrogenic effects. 17b-estradiol (Calbiochem) was resus-
pended in ethanol immediately prior to treatment. Cells were
treated with 10
27 M E2 or ethanol as a vehicle control for the
indicated duration. For LPS stimulation experiments, cells were
pre-treated with E2 for 24 hrs followed by administration of 10
ng/ml E. coli LPS (Sigma-Aldrich) for 12 hrs. Culture supernatants
were analyzed for CXCL8 production using the human CXCL8
Quantikine ELISA kit (R&D Systems) according to the manufac-
turer’s protocol.
RNA extraction and RT-PCR
Total RNA was extracted from cells using RNeasy Mini kit with
on-column DNase I treatment (Qiagen). RNA integrity and
concentration were determined using the RNA6000 Nano
LabChip kit (Agilent). 500 ng of RNA were reverse transcribed
using the SuperScript III First-Strand Synthesis System for RT-
PCR (Invitrogen) according to the manufacturer’s protocol. For
analysis of ERa transcripts, PCR was performed with Taq DNA
polymerase (Invitrogen) for 30 cycles using the primers listed in
Table 1. Cycling conditions were as follows: an initial 2 minute
denaturation at 95uC followed by 30 cycles consisting of 30 sec at
95uC, 30 sec at 57uC, and 1 min per kb DNA amplified at 72uC. A
final extension for 10 min at 72uC concluded the reactions.
Reactions without reverse transcriptase or without template served
as controls for genomic DNA contamination. 10 ml of PCR
product was analyzed by electropheresis on 1% agarose gels and
photographed under UV light.
TaqMan PCR
Real-time TaqMan PCR was used to quantify mRNA
expression of ERa and ERb. 0.5 ml of cDNA was added to
TaqMan Master Mix (Applied Biosystems) in accordance with the
manufacturer’s instructions. TaqMan validated primer/probe sets
for ERa and ERb (Applied Biosystems) directed toward the exon
3–4 and exon 4–5 boundaries, respectively, were used to amplify
target genes. A b-actin primer/probe set (Applied Biosystems) was
used as an internal control to normalize experimental gene
expression. In previous studies, we have shown that estradiol
treatment does not affect b-actin expression in human monocytes
and macrophages [7,58]. Amplification was carried out using the
Applied Biosystems 7300 Real-Time PCR system. Threshold cycle
number was determined using Opticon software and ER levels
were normalized to b-actin levels using the formula 2
2 (Et2Rt)
where Rt is the mean cycle threshold for the control gene and Et is
the mean threshold for the experimental gene. Cycling conditions
for TaqMan PCR consisted of an initial incubation at 50uC for 2
min and 95uC for 10 min followed by 40 cycles of 95uC for 15 sec
and 60uC for 1 min. Product accumulation was measured during
the extension phase and all samples were run in triplicate.
Preparation of lysates and immunoblot analysis
Whole cell lysates were prepared using M-PER mammalian
protein extraction reagent (Pierce) according to the manufacturer’s
instructions. Lysates were analyzed for total protein concentration
using a Micro BCA Protein Assay kit (Pierce). 25 mg of each lysate
were separated on 10% acrylamide gels and electrotransferred to
nitrocellulose membrane in Tris-glycine buffer with 20% metha-
nol. Membranes were blocked in 5% milk in 1X TBS and 0.1%
Tween-20 for 1 h at room temperature. Blots were then probed
with either mouse mAb TE111.5D11 (Abcam) for ERa or mouse
mAb ab16813 (Abcam) for ERb detection, followed by goat anti-
mouse HRP-conjugated secondary antibody (BioRad). To control
for protein loading, blots were probed for GAPDH expression
using mouse mAb 6C5 (American Research Products). Incuba-
tions with primary antibody were overnight at 4uC with rocking
and incubations with secondary antibody were performed at room
temperature for 45 min following thorough washing. Blots were
visualized using Supersignal chemiluminesence substrate (Pierce).
Images were scanned and signal density was quantified using the
ChemiImager 5500 software (Alpha Innotech).
Flow cytometric analysis
Surface expression of CD14, MHC II and CD16 were assessed
using CellQuest analysis software on a FACScan (BD Biosciences)
flow cytometer. Macrophages and monocytes that were cultured
as indicated in Figure 3 were incubated with normal human IgG (6
mg/ml) to block FcR-specific binding of mAbs and 40 mg/ml of
FITC conjugated antibodies AML-223 (anti-CD14), L243 (anti-
MHC II), or 3G8 (anti-CD16). The cells were washed and fixed in
1% MFF. Mean fluorescent intensity (MFI) was determined by the
geometric mean of fluorescence of the cells and unstained cells
served as a negative control.
Luciferase Reporter Plasmid Construction
The ERa F promoter was PCR amplified from human genomic
DNA using the forward primer 59CCTCTGTACTGGG-
TACTGGGAC39 and reverse primer 59CTTGAAGAGAAGAT-
TATCACTCAGAGACTGTCT39 and cloned into the pCR2.1-
TOPO vector using the TOPO TA Cloning kit (Invitrogen). The
F promoter was then sub-cloned into pGL4 luciferase reporter
vector (Promega) by digestion with KpnI and XhoI. Mutations were
introduced using the QuickChange site-directed mutagenesis kit
(Stratagene) as per the manufacturer’s recommendations. The 1/2
ERE was mutated from 59GGTCA39 to 59GGGCC39 using the
primer set 59GCATTTCCTAATTTCATGGGCCTAACAGC-
CTCCTGTCTACC39 and its general compliment. All plasmids
were sequenced prior to transfection.
Transient Transfection and Luciferase Assay
RAW264.7 cells were plated 24 hours before transfection at a
density of 2610
5 cells per well in 24-well tissue-culture dishes.
Cells were transfected using Lipofectamine 2000 (Invitrogen).
Transfection efficiency was normalized to Renilla activity by
cotransfection of 40 ng pRL-TK expression vector (Promega) and
transfection efficiencies typically ranged from 85%–90%. Cells
were incubated with 80 mg reporter plasmid, treated with 1610
27
estradiol 18 hours post-transfection and harvested with passive
lysis buffer (Promega). Luciferase activity was determined using the
dual-luciferase reporter assay system (Promega) and the Berthold
Centro LB960 luminometer. Data were analyzed in triplicate and
are represented as normalized relative light units (RLUs).
Statistical analysis
Results are presented as mean+/2SE. Statistical analysis was
performed using a paired Student’s t- test and significance was
achieved at p,0.05.
Supporting Information
Figure S1 Monocyte viability is not effected by E2 treatment.
Monocytes were cultured for 24, 48 or 72 hrs in the presence or
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Blue assay and data are represented as percent control.
Found at: doi:10.1371/journal.pone.0005539.s001 (0.92 MB TIF)
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